Evidence map›Paper›PMID 29209952›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018

Correction to: SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).

J M Sepúlveda-Sánchez, J Muñoz Langa, M Á Arráez, J Fuster, A Hernández Laín, G Reynés, V Rodríguez González, E Vicente, M Vidal Denis, Ó Gallego

Abstract readPublished Erratum
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

J M Sepúlveda-SánchezNeurooncology Unit, Hospital Universitario, 12 de Octubre, Madrid, Spain. juanmanuel.sepulveda@salud.madrid.org.ORCID http://orcid.org/0000-0003-4338-5804
J Muñoz LangaMedical Oncology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain.
M Á ArráezNeurosurgery Department, HRU Carlos Haya, Málaga, Spain.
J FusterMedical Oncology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
A Hernández LaínNeuropathology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.
G ReynésMedical Oncology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain.
V Rodríguez GonzálezRadiation Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.
E VicenteMedical Oncology Department, C.H.U. Insular-Materno Infantil de Gran Canaria, Las Palmas, Spain.
M Vidal DenisNeuroradiology Unit, HRU Carlos Haya, Málaga, Spain.
Ó GallegoMedical Oncology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The original version of this article unfortunately contained a mistake. Figure 3 was incorrect.

Identifiers

PMID29209952
PMCPMC6828215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.